PFE241129C24000
- 2.16
- +0.32+17.39%
Pfizer Newsroom
Berenberg Bank Maintains Pfizer(PFE.US) With Hold Rating, Raises Target Price to $29
Berenberg Bank Sticks to Their Hold Rating for Pfizer (PFE)
Morgan Stanley Sticks to Their Hold Rating for Pfizer (PFE)
Morgan Stanley Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $31
Leerink Partners Maintains Pfizer(PFE.US) With Hold Rating
Wolfe Research Initiates Pfizer at Underperform With $25 Price Target
Pfizer Analyst Ratings
Wolfe Research Downgrades Pfizer(PFE.US) to Sell Rating, Announces Target Price $25
Pfizer Initiated With an Underperform at Wolfe Research
UBS Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $31
UBS Remains a Hold on Pfizer (PFE)
CFRA Upgrades Pfizer(PFE.US) to Buy Rating, Cuts Target Price to $30
Jefferies Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $33
Jefferies Remains a Buy on Pfizer (PFE)
Daiwa Securities Adjusts Pfizer's Price Target to $28 From $34, Keeps Outperform Rating
Pfizer's Ponsegromab: A Promising Yet Uncertain Opportunity Influencing Hold Rating
Evercore Maintains Pfizer(PFE.US) With Buy Rating
Truist Financial Maintains Pfizer(PFE.US) With Buy Rating
Barclays Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $32
UBS Maintains Pfizer(PFE.US) With Hold Rating, Raises Target Price to $31